PPT-Nonalcoholic Fatty Liver Disease [NAFLD]

Masi Khaja MD Objectives Epidemiology Natural History Clinical Presentation Pathogenesis Approach to Diagnosis Treatment What is NAFLD Nonalcoholic Fatty Liver Disease NAFLD STEATOSIS. By Edward Harris. Dept. of Biochemistry. Liver structure overview. Sasse et al. 1992. Hepatocyte. Endothelial cell. Kupffer cell. Stellate cell. Space of Disse. How to purify SEC, HC, HSC. Liver . Perfusion. Look for it Children and adolescents-. Too!. Dr. . Shrish. . Bhatnagar. Consultant Pediatric Gastroenterologist. VPIMS & . ELMCH,Lucknow. Dedication. JNMC. SGPGIMS. Dr S K BHATNAGAR. Hepatomegaly. non-alcoholic fatty liver disease. Dr. . Abdulwahhab. S. Abdullah. CABM, FICMS-G&H. Alcoholic liver . disease. Alcoholic liver . disease (ALD) is . one of the most common causes of . chronic liver disease worldwide.. Fatty Liver Disease. Anna Christina Dela Cruz, MD. Division of Digestive Diseases and Nutrition . Conflict of Interest. None. Upon completion of this activity, participants will be able to: . Select appropriate diagnostic testing for the evaluation of gastrointestinal comorbidities in patients with diabetes.. adults. Dr.mousavi. -Abadan-. Khordad. 1397 . DEFINITIONS — Patients with nonalcoholic fatty liver disease (NAFLD) . have hepatic . steatosis. , . with or without . inflammation and fibrosis. . In addition, . New Advances for NAFLD/NASH NAFLD: A Spectrum of Disease Who Is at Risk for NAFLD and NASH? Prevalence of NAFLD in Europe Prevalence of NAFLD and NASH Predicted to Increase in Europe What Is the Burden of NAFLD in Europe? Hepatologist. East & North Hertfordshire NHS Trust. Royal Free London NHS Foundation Trust. ELF Research Group. University College London. Liver disease. Scale of the problem. Liver disease is the 5. About these slides. These slides provide highlights of new data presented at the EASL NAFLD Summit 2019. Please feel free to use, adapt and share these slides for your own personal use; however, please acknowledge EASL as the source. Non-Alcoholic Fatty Liver Disease (NAFLD)/ . Non-Alcoholic Steatohepatitis (NASH). Dr.. . Ranjitsinh. Devkar. Asst. Professor Department of Zoology, . The . M.S.University. of Baroda, Vadodara, India. Mohammad . Hassabi. (MD). Assistant Professor of Sports and Exercise Med. Dept.. Shahid. . Beheshti. University of Medical Sciences. Taleghani. Medical Center. Physical activity. Exercise. . Sports.  . Hideki Fujii. 1. , Shinya Fukumoto. 1. , Masaru Enomoto. 2. , Sawako Uchida-Kobayashi. 2. , Tatsuo Kimura. 1. , Akihiro Tamori. 2. , Yuji Nadatani. 1. , Shingo Takashima. 1. , Naoki Nishimoto. 3. Rohit . Pai. MD, FRCPC. Gastroenterology and Hepatology. Island Health and Pacific Digestive Health. Clinical Assistant Professor, UBC. Liver Care Clinic, Royal . Jubillee. Hospital. Disclosures. Research: Intercept. in Hepatocellular Carcinoma: . Real-World Experience and Treatment Sequencing with NASH/NAFLD Risk Factors. Sammy Saab, . MD, MPH, AGAF, FACG, FAASLD. Medical Director, Pfleger Liver Institute. Medical Director, Adult Liver Transplant Program. Diabetes. Hypertension. HDL < 1 . mmol. /L . Triglycerides > 1.7 . mmol. /L. Suspicion of NAFLD ?. Remember normal LFT’s do not rule out liver disease Exclude significant alcohol misuse (intermediate or high risk group in the alcohol related liver disease pathway) before diagnosing NAFLD via this pathway.